Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Michael Anthony Hollingsworth

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5255-8888; OpenAlex author ID A5026061991; NIH RePORTER profile ID 1891494. Sources: OpenAlex.

Their work

Papers
101 (first author 0, last author 11)
Trials
0
Grants
10
Labs led
2
Collaborators
411
Papers, trials and grants by year

2011: 3 papers, 1 grant · 2012: 4 papers, 2 grants · 2013: 6 papers · 2014: 2 papers · 2015: 5 papers, 2 grants · 2016: 5 papers · 2017: 5 papers · 2018: 4 papers, 1 grant · 2019: 9 papers · 2020: 9 papers · 2021: 9 papers · 2022: 10 papers, 1 grant · 2023: 4 papers · 2024: 9 papers · 2025: 6 papers · 2026: 11 papers, 3 grants

Papers 50 of 101

  1. A MUC1-ALIX complex regulates extracellular vesicle cargo loading with activated SRC to enhance pancreatic cancer progression. Last author DOI 10.1016/j.canlet.2026.218411↗
  2. MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2026.218927↗
  3. The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion. Co-author DOI 10.1016/j.devcel.2026.04.001↗
  4. Exosomal CircGANAB promotes cancer progression and immunotherapy resistance by degrading interacting RNAs and limiting T cell infiltration in pancreatic ductal… Co-author DOI 10.1016/j.drup.2026.101416↗
  5. Differences in collagen structure and organization in primary and metastatic pancreatic cancer and the effects of FOLFIRINOX treatment. Last author DOI 10.1016/j.mbplus.2026.100193↗
  6. Distinct glycosyltransferase expression governs organ-specific survival in pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-026-03896-5↗
  7. Hepatocytes promote liver metastasis of pancreatic cancer by providing serine. Co-author DOI 10.1038/s41586-026-11051-z↗
  8. KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Co-author DOI 10.1158/0008-5472.can-25-2630↗
  9. Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study. Co-author DOI 10.1158/1078-0432.ccr-25-4061↗
  10. AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors. Co-author DOI 10.1158/2159-8290.cd-25-1119↗
  11. Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer. Co-author DOI 10.1186/s12943-025-02340-8↗
  12. Co-treatment of ticagrelor and anti-PD-1 immunotherapy in tumor-associated macrophages reduces pancreatic cancer cell growth and migration through the TGF-β1/S… Co-author DOI 10.1016/j.biopha.2025.118695↗
  13. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Co-author DOI 10.1038/s41586-025-08927-x↗
  14. The Level of a Short Form of Multidrug Resistance-Associated Protein 1 Is Elevated in Plasma Small Extracellular Vesicles Derived From Patients With Pancreatic… Co-author DOI 10.1096/fj.202500874r↗
  15. Pancreatic cancer cachexia is mediated by PTHrP-driven disruption of adipose de novo lipogenesis Co-author DOI 10.1101/2025.06.03.657464↗
  16. Humanized Anti-MUC16 Antibody-Conjugated Contrast Agents for Magnetic Resonance Imaging of Pancreatic Cancer. Co-author DOI 10.3390/cancers17060957↗
  17. Neutrophil Dynamics Contribute to Disease Progression and Poor Survival in Pancreatic Cancer. Co-author DOI 10.3390/cancers17213541↗
  18. Engrailed-1 Promotes Pancreatic Cancer Metastasis. Co-author DOI 10.1002/advs.202308537↗
  19. Single-cell RNA-sequencing of human spleens reveals an IDO-1+ tolerogenic dendritic cell subset in pancreatic cancer patients that is absent in normal individu… Last author DOI 10.1016/j.canlet.2024.217321↗
  20. Coxsackievirus and adenovirus receptor expression facilitates enteroviral infections to drive the development of pancreatic cancer. Co-author DOI 10.1038/s41467-024-55043-x↗
  21. Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis. Co-author DOI 10.1038/s41556-024-01372-4↗
  22. Author Correction: Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 … Co-author DOI 10.1038/s41556-024-01417-8↗
  23. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  24. radioGWAS links radiome to genome to discover driver genes with somatic mutations for heterogeneous tumor image phenotype in pancreatic cancer. Co-author DOI 10.1038/s41598-024-62741-5↗
  25. The MUC1-HIF-1α signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling. Co-author DOI 10.1073/pnas.2315509121↗
  26. Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6. Co-author DOI 10.1158/1535-7163.mct-23-0868↗
  27. Uncovering Tumor-Promoting Roles of Activin A in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202207010↗
  28. Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2023.216150↗
  29. An intravenous pancreatic cancer therapeutic: Characterization of CRISPR/Cas9n-modified Clostridium novyi-Non Toxic. Co-author DOI 10.1371/journal.pone.0289183↗
  30. 3DGAUnet: 3D Generative Adversarial Networks with a 3D U-Net Based Generator to Achieve the Accurate and Effective Synthesis of Clinical Tumor Image Data for P… Co-author DOI 10.3390/cancers15235496↗
  31. Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis. Co-author DOI 10.1016/j.molcel.2022.06.005↗
  32. Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expressing Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.2c00203↗
  33. CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis. Co-author DOI 10.1038/s41388-021-02132-6↗
  34. Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling. Co-author DOI 10.1038/s41598-022-05660-7↗
  35. Mucin 5AC-Mediated CD44/ITGB1 Clustering Mobilizes Adipose-Derived Mesenchymal Stem Cells to Modulate Pancreatic Cancer Stromal Heterogeneity. Co-author DOI 10.1053/j.gastro.2022.02.032↗
  36. ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody. Co-author DOI 10.1158/1078-0432.ccr-21-1798↗
  37. MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. Co-author DOI 10.1158/1541-7786.mcr-21-0888↗
  38. Using Quantitative Imaging for Personalized Medicine in Pancreatic Cancer: A Review of Radiomics and Deep Learning Applications. Co-author DOI 10.3390/cancers14071654↗
  39. Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling. Co-author DOI 10.3390/ijms23105459↗
  40. Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma. Co-author PMID 35141005↗
  41. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans. Co-author DOI 10.1016/j.canlet.2021.01.015↗
  42. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer. Co-author DOI 10.1016/j.ymthe.2020.12.029↗
  43. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-020-01518-2↗
  44. Suppression of pancreatic cancer liver metastasis by secretion-deficient ITIH5. Co-author DOI 10.1038/s41416-020-01093-z↗
  45. Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-021-04176-w↗
  46. Effects of interobserver and interdisciplinary segmentation variabilities on CT-based radiomics for pancreatic cancer. Co-author DOI 10.1038/s41598-021-95152-x↗
  47. IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0368↗
  48. Plexin-B3 Regulates Cellular Motility, Invasiveness, and Metastasis in Pancreatic Cancer. Co-author DOI 10.3390/cancers13040818↗
  49. Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13092264↗
  50. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal. Co-author DOI 10.1016/j.bbcan.2020.188387↗

Grants 10

  1. Porcine Platforms For Technology Development In Pancreatic Cancer R01CA295693↗
  2. Pancreatic Cancer Detection Consortium U01CA210240↗
  3. MUC1 in Therapy Resistance U54CA274329↗
  4. Project 1: The Role and Mechanism(s) of MUC16 and MUC16-Cter in Potentiating PC Metastasis P01CA217798↗
  5. Tissue Core P50CA127297↗
  6. Early Diagnosis of Pancreatic Cancer U01CA111294↗
  7. Rapid Autopsy Program U54CA163120↗
  8. Studies on the Post-translational processing of MUC1 R01CA057362↗
  9. A novel combination therapy for the treatment of Pancreatic adenocarcinoma R03CA149857↗
  10. Autoantibodies Against Glycopeptide Epitopes as Serum Biomarkers of Cancer U01CA128437↗

Closest collaborators

The 25 strongest of 411 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paul M. Grandgenett · 42 shared papers, 1 shared grant, 2011–2026 · strength 6.53
  2. Pankaj Kumar Singh · 14 shared papers, 3 shared grants, 2011–2026 · strength 2.90
  3. Surinder K. Batra · 18 shared papers, 4 shared grants, 2011–2026 · strength 2.63
  4. Thomas C. Caffrey · 19 shared papers, 2011–2026 · strength 2.41
  5. Prakash Radhakrishnan · 16 shared papers, 2012–2026 · strength 1.93
  6. Kamiya Mehla · 14 shared papers, 2012–2026 · strength 1.64
  7. Joshua M.V. Mammen · 1 shared grant, 2026 · strength 1.26
  8. Satish Sagar · 8 shared papers, 2019–2026 · strength 1.26
  9. Surendra Kumar Shukla · 9 shared papers, 2017–2026 · strength 1.18
  10. Jean L. Grem · 9 shared papers, 2017–2026 · strength 1.12
  11. Christabelle Rajesh · 5 shared papers, 2022–2026 · strength 1.04
  12. Maneesh Jain · 5 shared papers, 1 shared grant, 2015–2026 · strength 1.01
  13. Aaron M. Mohs · 6 shared papers, 2018–2025 · strength 0.90
  14. Jixin Dong · 1 shared grant, 2026 · strength 0.86
  15. Clara S. Mundry · 4 shared papers, 2020–2026 · strength 0.83
  16. Ravi Kumar Thakur · 5 shared papers, 2022–2026 · strength 0.80
  17. Michael J. Baine · 6 shared papers, 2014–2024 · strength 0.79
  18. Jesse L. Cox · 6 shared papers, 2014–2026 · strength 0.77
  19. Ryan J. King · 6 shared papers, 2017–2026 · strength 0.77
  20. Dandan Zheng · 5 shared papers, 2020–2024 · strength 0.75
  21. Kuldeep Singh Attri · 6 shared papers, 2017–2024 · strength 0.73
  22. Nina V. Chaika · 7 shared papers, 2012–2024 · strength 0.68
  23. Rakesh K. Singh · 3 shared papers, 1 shared grant, 2015–2025 · strength 0.63
  24. Divya Murthy · 5 shared papers, 2017–2024 · strength 0.63
  25. Chunbo He · 4 shared papers, 2022–2026 · strength 0.62

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.